Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care
Jaguar Health (NASDAQ:JAGX) has appointed Susan Krizancic as National Sales Director for its family company Napo Pharmaceuticals. Krizancic, a biopharmaceutical industry veteran with 30 years of experience, will lead sales for Jaguar's commercialized oncology and HIV products. This includes the planned October 2024 launch of Gelclair, an FDA-approved oral mucositis prescription product for cancer supportive care.
Krizancic's appointment is expected to bolster Jaguar's commercial strategy, particularly in cancer and GI supportive care. The company will also continue to focus on sales of crofelemer (Mytesi), its FDA-approved drug for noninfectious diarrhea in adult HIV/AIDS patients on antiretroviral therapy. Jaguar's CEO, Lisa Conte, expressed confidence in Krizancic's ability to drive sales and execute the company's in-licensing growth strategy.
Jaguar Health (NASDAQ:JAGX) ha nominato Susan Krizancic come Direttore Nazionale delle Vendite per la sua azienda familiare Napo Pharmaceuticals. Krizancic, veterana dell'industria biofarmaceutica con 30 anni di esperienza, guiderà le vendite dei prodotti oncologici e per l'HIV commercializzati da Jaguar. Questo include il previsto lancio di Gelclair nell'ottobre 2024, un prodotto da prescrizione approvato dalla FDA per la mucosite orale nell'ambito della cura di sostegno ai pazienti affetti da cancro.
La nomina di Krizancic si prevede rafforzerà la strategia commerciale di Jaguar, in particolare nel campo della cura di sostegno per il cancro e per il tratto gastrointestinale. L'azienda continuerà anche a concentrarsi sulle vendite di crofelemer (Mytesi), il suo farmaco approvato dalla FDA per la diarrea non infettiva in pazienti adulti con HIV/AIDS in terapia antiretrovirale. L'amministratore delegato di Jaguar, Lisa Conte, ha espresso fiducia nella capacità di Krizancic di stimolare le vendite e di attuare la strategia di crescita attraverso l'in-licensing dell'azienda.
Jaguar Health (NASDAQ:JAGX) ha nombrado a Susan Krizancic como Directora Nacional de Ventas para su empresa familiar Napo Pharmaceuticals. Krizancic, veterana de la industria biofarmacéutica con 30 años de experiencia, liderará las ventas de los productos oncológicos y de VIH comercializados por Jaguar. Esto incluye el lanzamiento previsto de Gelclair en octubre de 2024, un producto de prescripción aprobado por la FDA para el tratamiento de la mucositis oral en el cuidado de apoyo para cáncer.
Se espera que la designación de Krizancic refuerce la estrategia comercial de Jaguar, especialmente en el cuidado de apoyo para el cáncer y el sistema gastrointestinal. La empresa también continuará enfocándose en las ventas de crofelemer (Mytesi), su medicamento aprobado por la FDA para la diarrea no infecciosa en pacientes adultos con VIH/SIDA en terapia antirretroviral. La CEO de Jaguar, Lisa Conte, expresó confianza en la capacidad de Krizancic para impulsar las ventas y ejecutar la estrategia de crecimiento por licencias de la compañía.
재규어 헬스(NASDAQ:JAGX)가 수잔 크리잔시치를 가족 기업인 나포 제약의 국가 영업 이사로 임명했습니다. 크리잔시치는 30년의 경력을 가진 생명공학 산업의 베테랑으로, 재규어의 상용화된 항암 및 HIV 제품의 판매를 이끌게 됩니다. 여기에는 2024년 10월 Gelclair 출시 예정이 포함되며, 이는 암 환자의 지지 치료를 위한 FDA 승인 경구용 점막염 처방 제품입니다.
크리잔시치의 임명은 특히 암 및 GI 지지 치료에서 재규어의 상업 전략을 강화할 것으로 예상됩니다. 이 회사는 또한 항레트로바이러스 요법을 받고 있는 성인 HIV/AIDS 환자의 비감염성 설사에 대한 FDA 승인 약물인 크로펠레머 (Mytesi)의 판매에 계속 집중할 것입니다. 재규어의 CEO인 리사 콘트는 크리잔시치가 판매를 촉진하고 회사의 라이센스 성장 전략을 실행할 수 있는 능력에 대해 확신을 표명했습니다.
Jaguar Health (NASDAQ:JAGX) a nommé Susan Krizancic au poste de Directrice Nationale des Ventes pour sa société familiale Napo Pharmaceuticals. Krizancic, vétérane de l'industrie biopharmaceutique avec 30 ans d'expérience, dirigera les ventes des produits commercialisés en oncologie et VIH de Jaguar. Cela inclut le lancement prévu de Gelclair en octobre 2024, un produit d’ordonnance approuvé par la FDA pour la mucosite orale dans le cadre des soins de soutien aux patients atteints de cancer.
La nomination de Krizancic devrait renforcer la stratégie commerciale de Jaguar, notamment dans le domaine des soins de soutien en oncologie et en gastro-entérologie. L'entreprise continuera également à se concentrer sur les ventes de crofelemer (Mytesi), son médicament approuvé par la FDA pour la diarrhée non infectieuse chez les adultes vivant avec le VIH/SIDA sous traitement antirétroviral. La PDG de Jaguar, Lisa Conte, a exprimé sa confiance dans la capacité de Krizancic à stimuler les ventes et à exécuter la stratégie de croissance par licence de l'entreprise.
Jaguar Health (NASDAQ:JAGX) hat Susan Krizancic zur Nationalen Vertriebsleiterin für ihr Familienunternehmen Napo Pharmaceuticals ernannt. Krizancic, eine erfahrene Fachkraft der biopharmazeutischen Industrie mit 30 Jahren Erfahrung, wird den Vertrieb der kommerzialisierten Onkologie- und HIV-Produkte von Jaguar leiten. Dazu gehört die geplante Markteinführung von Gelclair im Oktober 2024, einem von der FDA genehmigten Rezeptarzneimittel gegen orale Mukositis zur Unterstützung von Krebspatienten.
Die Ernennung von Krizancic wird voraussichtlich die kommerzielle Strategie von Jaguar stärken, insbesondere im Bereich der Unterstützungsbehandlung für Krebs und gastrointestinalen Problemen. Das Unternehmen wird sich auch weiterhin auf den Verkauf von Crofelemer (Mytesi) konzentrieren, seinem von der FDA genehmigten Medikament gegen nichtinfektiöse Durchfälle bei erwachsenen HIV/AIDS-Patienten, die eine antiretrovirale Therapie erhalten. Die CEO von Jaguar, Lisa Conte, äußerte sich zuversichtlich über Krizancics Fähigkeit, den Verkauf anzukurbeln und die Wachstumsstrategie des Unternehmens durch Lizenzierung umzusetzen.
- Appointment of experienced industry veteran Susan Krizancic as National Sales Director
- Planned October 2024 launch of FDA-approved Gelclair for cancer supportive care
- Expansion of product portfolio with Gelclair as the third commercialized prescription product
- Continued focus on sales of FDA-approved crofelemer (Mytesi) for HIV-related diarrhea
- None.
FDA-approved Gelclair® is company's third commercialized prescription product
Susan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals
SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar family company Napo Pharmaceuticals.
"Sue is a dynamic and proven commercial leader with 30 years of experience in the biopharmaceuticals industry - including 15 years of recent experience in the oncology market - building high-performing teams and exceeding sales targets. We are thrilled she has joined our team in the important role of National Sales Director at Napo," said Lisa Conte, Jaguar's president and CEO. "We are confident that her extensive sales and commercial experience will prove invaluable as we prepare for our planned October 2024 commercial launch of the FDA-approved oral mucositis prescription product Gelclair, continue to evolve and execute our in-licensing growth strategy in the areas of cancer and GI supportive care, and continue to focus on sales of crofelemer, our novel oral prescription drug - FDA-approved under the brand name Mytesi® - for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy."
"I am very happy to have joined the Jaguar/Napo team," Krizancic said. "I look forward to helping Jaguar drive sales of the company's suite of novel, FDA-approved prescription products that address significant unmet supportive care needs for patients with complex disease states like cancer and HIV."
Susan Krizancic is an accomplished pharmaceutical and biotech industry leader with 30 years of experience in building high performing teams. Most recently, she served as a member of the sales leadership team in the role of Regional Business Director with Mirati Therapeutics, building out the commercial sales organization and successfully launching the first commercial targeted cancer therapy for Mirati. Prior to joining Mirati, Sue spent 5 years at Astra Zeneca in roles of increasing responsibility, including US and Global Director of Leadership Development for the Oncology Business Unit. As a sales leader at Astra Zeneca, she played a critical role in building out two sales teams for commercial franchises and was appointed field lead for the company's alliance with Daiichi Sankyo. Prior experience includes four years at Bayer Oncology, recognized with two national leadership awards, and 18 years at GSK, gaining breadth of experience in various roles including sales leadership, marketing, training and development, market access and sales operations. Sue's extensive experience in commercial roles includes successfully launching innovative therapies and expanding the market with mature products.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
About Gelclair®
INDICATIONS
GELCLAIR® has a mechanical action indicated for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including oral mucositis/stomatitis (may be caused by chemotherapy or radiation therapy), irritation due to oral surgery, traumatic ulcers caused by braces or ill-fitting dentures, or disease. Also, indicated for diffuse aphthous ulcers.
IMPORTANT SAFETY INFORMATION
Do not use GELCLAIR if there is a known or suspected hypersensitivity to any of its ingredients.
No adverse effects have been reported in clinical trials, although postmarketing reports have included infrequent complaints of burning sensation in the mouth.
If GELCLAIR is swallowed accidentally, no adverse effects are anticipated.
If no improvement is seen within 7 days, a physician should be consulted.
You are encouraged to report negative side effects of prescription medical products to the FDA.
Visit www.fda.gov/safety/medwatch, call 1-855-273-0468 or fill-in the form at this link.
Please see full Prescribing Information at:
https://gelclair.com/assets/Gelclair_PI_Decemeber_2021.pdf
About Mytesi®
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will initiate the Gelclair commercial launch in October 2024, and Jaguar's expectation that it will continue to evolve and execute its in-licensing growth strategy in the areas of cancer and GI supportive care. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
Who did Jaguar Health (JAGX) appoint as National Sales Director?
When is Jaguar Health (JAGX) planning to launch Gelclair?
What are the main products Jaguar Health (JAGX) is focusing on?
What is Susan Krizancic's experience in the biopharmaceutical industry?
